Compare BridgeBio Pharma Inc (BBIO) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Johnson Controls International PLC — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while Johnson Controls International PLC trades at $143 (market cap $88.61B). The key difference: Johnson Controls International PLC is far larger — about 5.4× BridgeBio Pharma Inc's market cap, and Johnson Controls International PLC pays a 1.1% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | JCI | |
|---|---|---|
Market Cap | $16.46B | $88.61B |
Sector | Health | Industrials |
52-Week High | $90.17 | $148.21 |
52-Week Low | $44.81 | $103.24 |
Enterprise Value | $18.02B | $97.44B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Johnson Controls International (JCI) trades at $143.93, up 0.78% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $1.33. Revenue for 2025 reached $23.60 billion, with net income surging to $3.29 billion, reflecting a robust profit margin of 13.94%. Recent corporate actions include a $0.40 dividend payment scheduled for July 2026, and positive news flow highlights growth in smart home and building efficiency markets.
JCI presents a favorable investment case driven by earnings momentum, solid profitability, and a unanimous analyst buy consensus with a $158.29 price target. Key risks include elevated valuation multiples (P/E of 43.67) and rising debt-to-asset ratios, which could pressure returns if growth slows. The stock's proximity to its 52-week high suggests limited near-term upside, but operational execution and sector tailwinds support a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
